Obiettivo Nox Medical will develop and bring to market disruptive technology in sleep diagnostics to address an epidemic which costs Europe more than € 300 billion annually. Nox Medical is a leading company in the field of sleep diagnostics equipment. Based on our experience and market positioning we plan to revolutionize sleep diagnostics by improving the diagnostic power of our products and making them accessible to a much larger market. Current sleep diagnosis methods and criteria are based on findings which were made before computers were common place in the hospital environment. Since then, a range of biomarkers and diagnostics protocols have been discovered, validated, and published in scientific journals. These biomarkers and diagnostics protocols have not been integrated into routine diagnosis. This is partly due to technological challenges and partly due to the conservative nature of medicine. By adopting these biomarkers and diagnostics protocols into state of the art diagnostics products, Nox Medical is bridging the gap between research and clinical application. The resulting products will allow more sleep studies being performed in the home environment, instead of being performed inside a hospital. This will allow better patient stratification, reduction of cost, and make sleep diagnosis available to a much larger market. The results of the project open up a possibility of revolutionising the business model behind sleep diagnostics by offering sleep diagnostics as a service, similar to a model commonly used in software marketing today. Campo scientifico medical and health sciencesclinical medicinepsychiatrysleep disordersnatural sciencescomputer and information sciencesartificial intelligencesocial scienceseconomics and businessbusiness and managementbusiness modelssocial sciencespsychologyergonomicsnatural sciencescomputer and information sciencesdata sciencedata processing Programma(i) H2020-EU.2.1.1. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Information and Communication Technologies (ICT) Main Programme H2020-EU.2.3.1. - Mainstreaming SME support, especially through a dedicated instrument Argomento(i) SMEInst-01-2016-2017 - Open Disruptive Innovation Scheme Invito a presentare proposte H2020-SMEInst-2016-2017 Vedi altri progetti per questo bando Bando secondario H2020-SMEINST-2-2016-2017 Meccanismo di finanziamento SME-2 - SME instrument phase 2 Coordinatore NOX MEDICAL EHF Contribution nette de l'UE € 2 000 000,00 Indirizzo KATRINARTUNI 2 105 Reykjavik Islanda Mostra sulla mappa PMI L’organizzazione si è definita una PMI (piccola e media impresa) al momento della firma dell’accordo di sovvenzione. Sì Regione Ísland Ísland Höfuðborgarsvæði Tipo di attività Private for-profit entities (excluding Higher or Secondary Education Establishments) Collegamenti Contatta l’organizzazione Opens in new window Partecipazione a programmi di R&I dell'UE Opens in new window Rete di collaborazione HORIZON Opens in new window Costo totale € 2 883 150,00
